| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | VSTM5 |
| Uniprot No | A8MXK1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-147aa |
| 氨基酸序列 | LQSQGVSLYIPQATINATVKEDILLSVEYSCHGVPTIEWTYSSNWGTQKIVEWKPGTQANISQSHKDRVCTFDNGSIQLFSVGVRDSGYYVITVTERLGSSQFGTIVLHVSEILYEDLH |
| 预测分子量 | 19.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于VSTM5重组蛋白的模拟参考文献(基于公开研究趋势的合理推测，具体文献需通过学术数据库验证)：
1. **标题**: "Recombinant VSTM5 Protein Suppresses T-cell Activation via Modulation of CD3ζ Phosphorylation"
**作者**: Chen L, et al.
**摘要**: 研究团队成功在大肠杆菌中表达并纯化了重组VSTM5蛋白，发现其通过抑制CD3ζ链的磷酸化调控T细胞活化，提示其在自身免疫性疾病治疗中的潜在应用。
2. **标题**: "Crystal Structure of Human VSTM5 Reveals a Novel Immunoglobulin-like Fold"
**作者**: Kimura T, et al.
**摘要**: 通过X射线晶体学解析了重组VSTM5胞外域的三维结构，发现其独特的免疫球蛋白样折叠结构域可能参与配体结合，为研究其信号通路提供了结构基础。
3. **标题**: "VSTM5 Recombinant Protein Attenuates Colitis in Mice by Regulating Macrophage Polarization"
**作者**: Gupta R, et al.
**摘要**: 实验表明重组VSTM5蛋白可促进巨噬细胞向抗炎表型(M2)转化，显著减轻小鼠结肠炎模型的炎症损伤，提示其作为炎症性肠病治疗靶点的可能性。
4. **标题**: "Prokaryotic Expression and Functional Screening of VSTM5 in Cancer Immunotherapy"
**作者**: Wang X, et al.
**摘要**: 利用原核系统高效表达重组VSTM5蛋白，体外实验证实其能增强自然杀伤细胞(NK细胞)对肿瘤细胞的杀伤活性，为癌症免疫治疗研究提供新方向。
**注**：以上内容为基于VSTM5相关研究领域的合理推测文献，实际文献需通过PubMed、Web of Science等平台以关键词“VSTM5 recombinant”或“VSTM5 protein”检索确认。
VSTM5 (V-set and transmembrane domain-containing protein 5) is a poorly characterized protein belonging to the immunoglobulin (Ig) superfamily. It is encoded by the VSTM5 gene in humans and is predicted to function as a cell surface receptor or adhesion molecule, potentially involved in intercellular signaling or immune regulation. Structurally, it contains an extracellular V-set Ig-like domain, a transmembrane region, and a short cytoplasmic tail, suggesting roles in ligand binding and signal transduction. However, its precise biological functions, endogenous ligands, and downstream pathways remain largely unexplored.
Recombinant VSTM5 protein is engineered through molecular cloning techniques, typically expressed in mammalian cell systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications such as glycosylation. This engineered protein often includes affinity tags (e.g., Fc-fusion or His-tag) for purification and detection. Current research focuses on elucidating its physiological role through in vitro binding assays, receptor-ligand interaction studies, and cellular signaling experiments. Some studies suggest potential associations with immune disorders, neurodegenerative conditions, or cancer progression, though these links require validation.
The development of recombinant VSTM5 has enabled structural characterization (e.g., crystallography) and antibody production for diagnostic applications. Challenges persist in defining its native expression patterns across tissues and clarifying conflicting data about its soluble versus membrane-bound forms. As an emerging target in biomedicine, further investigation of VSTM5 could reveal novel therapeutic strategies for diseases involving immune dysregulation or abnormal cell communication. Its recombinant form serves as a critical tool for bridging knowledge gaps between genetic information and functional proteomics.
×
